Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MER683
- Development stage
- Preclinical
- Lead developer
- Merida Biosciences
01
Overview
MER683 is a biologic therapeutic candidate being developed by Merida Biosciences for the treatment of primary membranous nephropathy (pMN). It is designed to clear pathogenic autoantibodies that target the phospholipase A2 receptor (PLA2R), which are the primary drivers of glomerular damage in this autoimmune kidney disease. By specifically removing these autoantibodies from the circulation, MER683 aims to halt the progression of podocyte injury and promote renal recovery. The program is currently in the IND-enabling stage of development.
- Other names
- PLA2R-specific AgFcPLA-2R-specific AgFcPLA 2R-specific AgFcPLA2R-specific antigen-Fc fusion proteinsPLA-2R-specific antigen-Fc fusion proteinsPLA 2R-specific antigen-Fc fusion proteins
02
Targets
PLA2R1 (Phospholipase A2 receptor 1)
Beyond the preview
Go deeper on MER683.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MER683.